
	Three Months Ended June 27, 2026
	U.S.		International		Consolidated
Net sales	$	134,465	$	18,743	$	153,208
Adjusted cost of sales(a)	30,966		6,683
Adjusted selling expense(b)	39,050		3,392
Adjusted marketing expense(b)	6,051		784
Adjusted general and administrative expense(b)	25,290		3,041
Adjusted research and development expense(c)	2,915		1
Adjusted other segment (income) loss(d)	(295)		67
Adjusted EBITDA	30,488		4,775		35,263
Reconciliation to income before taxes:
Interest expense, net					(4,068)
Depreciation and amortization					(10,945)
Restructuring costs					415
Shareholder litigation costs					(22)
Equity compensation					(5,041)
Debt refinancing					(2)
Other items(e)					(292)
Income before income taxes					$	15,308


	Three Months Ended June 28, 2025
	U.S.		International	Consolidated
Net sales	$	128,775	18,885	$	147,660
Adjusted cost of sales(a)	28,218		6,749
Adjusted selling expense(b)	37,351		3,220
Adjusted marketing expense(b)	6,657		933
Adjusted general and administrative expense(b)	24,791		2,519
Adjusted research and development expense(c)	2,917		18
Adjusted other segment loss(d)	366		170
Adjusted EBITDA	28,475		5,276	33,751
Reconciliation to income before taxes:
Interest expense, net				(7,494)
Depreciation and amortization				(12,049)
Shareholder litigation costs				(13)
Equity compensation				(3,643)
Debt refinancing				(172)
Loss on disposal of a business				(1)
Other items(e)				(66)
Income before income taxes				$	10,313


	Six Months Ended June 27, 2026
	U.S.		International		Consolidated
Net sales	$	250,910	$	34,387	$	285,297
Adjusted cost of sales(a)	55,864		13,018
Adjusted selling expense(b)	77,290		6,714
Adjusted marketing expense(b)	11,937		1,537
Adjusted general and administrative expense(b)	49,532		5,622
Adjusted research and development expense(c)	5,204		1
Adjusted other segment income(d)	(547)		(53)
Adjusted EBITDA	51,630		7,548		59,178
Reconciliation to income before taxes:
Interest expense, net					(8,394)
Depreciation and amortization					(22,150)
Restructuring costs					(39)
Shareholder litigation costs					(41)
Equity compensation					(8,305)
Debt refinancing					(2)
Other items(e)					(422)
Income before income taxes					$	19,825


	Six Months Ended June 28, 2025
	U.S.		International		Consolidated
Net sales	$	239,295	$	32,241	$	271,536
Adjusted cost of sales(a)	53,615		11,907
Adjusted selling expense(b)	72,067		6,419
Adjusted marketing expense(b)	12,968		1,804
Adjusted general and administrative expense(b)	48,108		4,485
Adjusted research and development expense(c)	5,742		21
Adjusted other segment loss(d)	1,265		172
Adjusted EBITDA	45,530		7,433		52,963
Reconciliation to income before income taxes:
Interest expense, net					(15,003)
Depreciation and amortization					(23,914)
Shareholder litigation costs					(36)
Equity compensation					(6,057)
Debt refinancing					(172)
Loss on disposal of a business					(82)
Other items(e)					(803)
Income before income taxes					$	6,896

(b)Adjusted selling, general and administrative expense, as used in the calculation of segment Adjusted EBITDA, excludes certain acquisition and related costs, shareholder litigation costs, certain restructuring costs, asset impairments, debt refinancing costs, equity-based compensation expense, and other segment items, including costs associated with strategic transactions, such as potential divestitures, and a transformative project to redesign systems and information processing.

(c)Adjusted research and development expense used in calculating segment Adjusted EBITDA excludes depreciation and amortization, and equity-based compensation expense.

(d)Adjusted other segment (income) expense primarily consists of foreign currency transaction and remeasurement gains and losses and other certain nonrecurring items.

(e)During the three and six months ended June 27, 2026, other items primarily consisted of strategic transaction costs. During the three and six months ended June 28, 2025, other items primarily consisted of expenses related to the divestiture of the Advanced Rehabilitation Business.